Apollo Hospitals launches Super Speciality Center in Dadar to expand access to advanced care in Mumbai

Apollo Hospitals has launched its Super Speciality Center in Dadar, Mumbai, expanding access to advanced medical care in the city. The Centre will provide super-speciality services across cardiology, neurology, oncology, gastroenterology, orthopaedics, transplantation and pulmonology, supported by diagnostics, robotics-enabled care and 24×7 clinical access.

The launch was attended by Arunesh Punetha, Regional CEO – Western Region, along with Apollo experts including Dr Anil D’Cruz, Director Oncology and Senior Head and Neck Oncology Surgeon; Dr Deepak Gautam, Senior Consultant Orthopaedic and Robotic Joint Replacement Surgeon; Dr Dipalee Borade, Consultant Radiation Oncology; Dr Jyoti Bajpai, Lead Consultant, Medical and Precision Oncology; and Dr Sumeet Pawar, Consultant Spine and Neurosurgeon, along with members of the community.

Apollo Hospitals stated that nearly 8,000 patients from Mumbai travel to Apollo Hospitals Navi Mumbai every year for advanced care, with many undertaking repeated visits during the course of treatment. As Apollo Navi Mumbai approaches its 10th anniversary in November, the Dadar centre has been launched to bring clinical expertise and continuity of care closer to patients and families in Mumbai.

Dr Anil D’Cruz said, “At Apollo, we believe advanced healthcare should not only be world-class, but also easier to access consistently. Over the years, thousands of patients from Mumbai have travelled to Navi Mumbai for specialised treatment, often multiple times during the course of care. The launch of our Dadar Centre reflects our commitment to reducing that burden and ensuring patients can access Apollo’s trusted specialists, advanced diagnostics, and integrated care pathways closer to home. This is not just an expansion of infrastructure, but an expansion of patient-centric care.”

According to Apollo Hospitals, the Centre is expected to reduce the burden of nearly 30 kilometres of travel per visit for patients requiring ongoing treatment, enabling consultations, follow-up and continuity of care. The company stated that this would be particularly relevant for oncology patients, individuals recovering post-transplant, and those managing chronic conditions requiring frequent visits.